<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628832</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT2489</org_study_id>
    <nct_id>NCT04628832</nct_id>
  </id_info>
  <brief_title>Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms</brief_title>
  <official_title>Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minnesota Management and Budget Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minnesota Board of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite an enormous policy response, opioid prescribing remains well above historical levels&#xD;
      and harms from opioids continue to mount. Nearly all states have Prescription Monitoring&#xD;
      Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research&#xD;
      suggests these systems only deliver benefits when health care professionals are required to&#xD;
      use them. Even with PMP mandates in place, providers may be unaware of the dangers of&#xD;
      co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk&#xD;
      of overdose and death. Working with the Minnesota state government, the investigators will&#xD;
      mail letters to guideline-discordant opioid prescribers that either highlight an upcoming&#xD;
      legally mandated requirement to check the PMP before prescribing an opioid, inform and&#xD;
      educate providers about patients filling concurrent prescriptions and the dangers of such&#xD;
      co-prescribing, or both. Study participants will be randomized to receive no intervention or&#xD;
      one of the three treatment letters. Using administrative data, the investigators will track&#xD;
      effects of the letters on not only prescribing but also PMP usage and queries. Findings form&#xD;
      the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving&#xD;
      overprescribing. Results will inform future work by state and local policymakers to make&#xD;
      opioid prescribing safer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Actual">July 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Patients with Co-Prescriptions</measure>
    <time_frame>60 days</time_frame>
    <description>The number of patients with co-prescriptions from the prescriber in the 60 days after the letters are sent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Prescribers Checking PMP</measure>
    <time_frame>60 days</time_frame>
    <description>Indicator for whether the prescriber checks the PMP at least once in the 60 days after the letters are sent.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12000</enrollment>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>PMP Use Mandate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prescribing Information</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prescribing Information + PMP Use Mandate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control / As-Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PMP Use Mandate Letter</intervention_name>
    <description>A letter with reminders about the mandate to check the PMP when prescribing opioids.</description>
    <arm_group_label>PMP Use Mandate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prescribing Information Letter</intervention_name>
    <description>A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.</description>
    <arm_group_label>Prescribing Information</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prescribing Information + PMP Use Mandate Letter</intervention_name>
    <description>A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.</description>
    <arm_group_label>Prescribing Information + PMP Use Mandate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Wrote concurrent prescription for opioids and benzodiazepines OR opioids and&#xD;
             gabapentinoids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specialization in oncology or palliative medicine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Sacarny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mireille Jacobson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Powell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RAND</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minnesota Board of Pharmacy</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Management and Budget Agency</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioids</keyword>
  <keyword>prescribing</keyword>
  <keyword>benzodiazepines</keyword>
  <keyword>gabapentinoids</keyword>
  <keyword>clinical guidelines</keyword>
  <keyword>overprescribing</keyword>
  <keyword>Benzodiazepine Use</keyword>
  <keyword>Gabapentin Use</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

